Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sailish Honap

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Joint Bone Spine|May 25, 2025
Advanced combination therapy in inflammatory bowel diseaseCaroline Morizot, Léa Sequier, Jean-Yves Jouzeau, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Depression, anxiety, and stress among inflammatory bowel disease patients during COVID-19: A UK cohort studyRaphael P Luber, Alexa Duff, Polychronis Pavlidis, et al.
Journal of Crohn'S & Colitis|December 28, 2021
Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and TreatmentSailish Honap, Susanna Meade, Ashley Spencer, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics|December 11, 2025
Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary centerMichael Colwill, Jessica Padley, Umang Qazi, et al.
Frontline Gastroenterology|July 6, 2023
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?Susanna Meade, Emma Routledge, Esha Sharma, et al.
Frontline Gastroenterology|October 17, 2022
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort studySailish Honap, Lulia Al-Hillawi, Samantha Baillie, et al.
Frontline Gastroenterology|May 19, 2020
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal responseMark A Samaan, Siddharth Birdi, Maria Sierra Morales, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 8, 2025
Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysisSudheer K Vuyyuru, Nader Shaban, Yuhong Yuan, et al.
Alimentary Pharmacology & Therapeutics|July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switchRaphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
Journal of Crohn'S & Colitis|April 14, 2020
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK ExperienceSailish Honap, Desmond Chee, Thomas P Chapman, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Joint Bone Spine|May 25, 2025
Advanced combination therapy in inflammatory bowel diseaseCaroline Morizot, Léa Sequier, Jean-Yves Jouzeau, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|January 24, 2022
Depression, anxiety, and stress among inflammatory bowel disease patients during COVID-19: A UK cohort studyRaphael P Luber, Alexa Duff, Polychronis Pavlidis, et al.
Journal of Crohn'S & Colitis|December 28, 2021
Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and TreatmentSailish Honap, Susanna Meade, Ashley Spencer, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics|December 11, 2025
Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary centerMichael Colwill, Jessica Padley, Umang Qazi, et al.
Frontline Gastroenterology|July 6, 2023
How achievable are STRIDE-II treatment targets in real-world practice and do they predict long-term treatment outcomes?Susanna Meade, Emma Routledge, Esha Sharma, et al.
Frontline Gastroenterology|October 17, 2022
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort studySailish Honap, Lulia Al-Hillawi, Samantha Baillie, et al.
Frontline Gastroenterology|May 19, 2020
Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal responseMark A Samaan, Siddharth Birdi, Maria Sierra Morales, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 8, 2025
Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review With Meta-analysisSudheer K Vuyyuru, Nader Shaban, Yuhong Yuan, et al.
Alimentary Pharmacology & Therapeutics|July 5, 2021
An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switchRaphael P Luber, Rhona O'Neill, Sukhpreet Singh, et al.
Journal of Crohn'S & Colitis|April 14, 2020
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK ExperienceSailish Honap, Desmond Chee, Thomas P Chapman, et al.
Pageof 6